2,3-dihydro-1H-indole compounds

A pharmaceutical composition comprising a compound of the formula:

• wherein:
• R1a is hydrogen, methyl, ethenyl, cyano, fluoro, chloro, fluoromethyl, or difluoromethyl;
• R1b is hydrogen, fluoro, or chloro;
• R1c is hydrogen, hydroxy, fluoro, benzyloxy, or hydroxyethylamino;
• R2 is hydrogen or methyl;
• R2a is hydrogen or methyl;
• and
• R3a is tetrahydropyranyl;
• with one or more pharmaceutically acceptable excipients, carriers or diluents.

A method of treating a patient with a cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma comprising administering to the patient an effective amount of a compound of the formula:

• wherein:
• R1a is hydrogen, methyl, ethenyl, cyano, fluoro, chloro, fluoromethyl, or difluoromethyl;
• R1b is hydrogen, fluoro, or chloro;
• R1c is hydrogen, hydroxy, fluoro, benzyloxy, or hydroxyethylamino;
• R2 is hydrogen or methyl;
• R2a is hydrogen or methyl;
• and
• R3a is tetrahydropyranyl.